Systemic anti-EGFR medicines, such as cetuximab (CXT) and nimotuzumab (NTZ), have shown modest efficacy in clinical trials for nasopharyngeal cancer [10], but the results have been inconsistent [11–13]. Here, EGFR is linked to nasopharyngeal carcinoma.